Antioxidant pill may shield kidneys from chemo damage

NCT ID NCT07564479

Recruiting now Symptom relief Sponsor: Minia University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking alpha-lipoic acid, a natural antioxidant, can prevent kidney damage in cancer patients receiving cisplatin chemotherapy. About 50 adults with solid tumors will receive either alpha-lipoic acid or a placebo alongside their chemo. Researchers will monitor kidney function and quality of life to see if the supplement helps.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: alpha-lipoic acid
What this could lead to: If it works, this could offer a simple way to reduce kidney damage from cisplatin chemotherapy, helping patients complete their cancer treatment with fewer complications.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. Alpha-lipoic acid might not provide enough protection, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CISPLATIN NEPHROTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cisplatin toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CISPLATIN NEPHROTOXICITY NEPHROTOXICITY

Contacts and locations

Locations

Minia University Hospital
RECRUITING

Minya, Minya Governorate, 61111, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.